Platform Technology
BEPO® Technology
AIC's therapies utilize BEPO®, Medincell's cutting-edge Long-Acting Injectable polymer platform — a clinically validated, commercially proven
drug delivery system.
The Platform
What is BEPO®?
BEPO® is a biodegradable, injectable sustained-release technology developed by Medincell (Montpellier, France; EPA: MEDCL). It is based on a viscous non-aqueous copolymer mixture of polylactic acid (PLA) and polyethylene glycol (PEG) that, upon contact with aqueous fluids, self-assembles into a semi-solid depot at the site of injection.
The depot slowly biodegrades over days to weeks, releasing the encapsulated drug in a controlled, sustained manner — eliminating the need for repeated dosing and maintaining therapeutic concentrations at the target site.
The technology is ready-to-use, requires no reconstitution or mixing, and does not require specialized training to administer — making it highly practical for surgical and clinical settings.
Biodegradable
PLA-PEG polymer safely degrades in biological tissue — no removal required.
Injectable Depot
Viscous liquid injected at the target site; solidifies on contact with aqueous fluid.
Sustained Release
Controlled drug release over days to weeks from a single administration.
Ready-to-Use
No mixing, reconstitution, or specialized equipment required.
Versatile
Compatible with a broad range of small molecule drugs and biologics.
Proven in the Clinic
Commercial Validation
FDA Approved — April 2023
UZEDY® (risperidone)
The first commercial product based on BEPO® technology. Marketed in the United States by Teva Pharmaceuticals for the treatment of schizophrenia.
Therapeutic plasma concentrations are achieved within 6–24 hours after a single subcutaneous injection, with dosing intervals of one or two months.
This approval demonstrates BEPO® has successfully navigated:
Large-scale GMP manufacturing
Global regulatory review
FDA approval
Commercial launch in the United States
Industry Validation
Strategic Pharmaceutical Partnerships
Medincell has established collaborations with leading global pharmaceutical companies to apply BEPO® technology across multiple therapeutic areas.
CNS / Psychiatry
Teva Pharmaceuticals
Teva licensed BEPO® technology (commercialized under the name SteadyTeq™) for long-acting injectable antipsychotics in a deal valued at up to $300M in milestones plus royalties. UZEDY® is the first approved product from this collaboration.
Additional programs, including long-acting olanzapine, remain in development.
Immunology / Specialty
AbbVie
In April 2024, AbbVie entered into a strategic co-development and licensing agreement with Medincell covering up to six long-acting injectable programs across multiple therapeutic areas. Medincell received a $35 million upfront payment and is eligible for up to $1.9 billion in development and commercial milestones ($315 million per program), plus mid-single to low-double-digit royalties on worldwide net sales.
Additional licensees include the Bill & Melinda Gates Foundation (global health applications) and Corbion (biomaterials), further demonstrating the breadth of BEPO®'s applicability and Medincell's position as a leading sustained-release drug delivery company.
Learn More About F14
See how BEPO® technology is applied in AIC's lead program for post-TKR pain and inflammation.